The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lutrate 3 month Depot 22.5 mg powder and solvent for prolonged-release suspension for injection



GP-PHARM, S.A.PA1766/002/002

Main Information

Trade NameLutrate 3 month Depot 22.5 mg powder and solvent for prolonged-release suspension for injection
Active SubstancesLeuprorelin acetate
Dosage FormPowder and solvent for prolonged-release suspension for injection
Licence HolderGP-PHARM, S.A.
Licence NumberPA1766/002/002

Group Information

ATC CodeL02AE Gonadotropin releasing hormone analogues
L02AE02 leuprorelin

Status

License statusAuthorised
Licence Issued17/07/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back